Group a Streptococcus strains circulating during scarlet fever epidemic, Beijing, China, 2011

Emerging Infectious Diseases

Volumn 19, Issue 6, 2013, Pages 909-915

  Yang, Peng ^a,b   Peng, Xiaomin ^a,b   Zhang, Daitao ^a,b   Wu, Shuangsheng ^a,b   Liu, Yimeng ^a,b   Cui, Shujuan ^a,b   Lu, Guilan ^a,b   Duan, Wei ^a,b   Shi, Weixian ^a,b   Liu, Shuang ^a,b   Li, Jing ^a,b   Wang, Quanyi ^a,b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN DERIVATIVE; SUPERANTIGEN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CHILD; CHINA; CLINICAL FEATURE; DISEASE SEVERITY; DISEASE SURVEILLANCE; DNA EXTRACTION; FEMALE; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PHARYNGITIS; PRESCHOOL CHILD; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; SCARLET FEVER; SEVERE ACUTE RESPIRATORY SYNDROME; STREPTOCOCCUS GROUP A; BACTERIUM; BACTERIUM IDENTIFICATION; BEIJING; CLASSIFICATION; DRUG EFFECT; EMM TYPE; EPIDEMIC; GAS; GENETICS; HEALTH SURVEY; HISTORY; MICROBIAL SENSITIVITY TEST; RISK FACTOR; STREPTOCOCCUS PYOGENES; SURVEILLANCE;

ANTIMICROBIAL DRUG SUSCEPTIBILITY; BACTERIA; BEIJING; CHINA; EMM TYPE; EPIDEMIC; GAS; GROUP A STREPTOCOCCUS; PEOPLE'S REPUBLIC OF CHINA; PHARYNGITIS; SCARLET FEVER; SUPERANTIGEN; SURVEILLANCE;

BACTERIAL TYPING TECHNIQUES; CHILD; CHILD, PRESCHOOL; CHINA; DISEASE OUTBREAKS; EPIDEMICS; HISTORY, 21ST CENTURY; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; PUBLIC HEALTH SURVEILLANCE; RISK FACTORS; SCARLET FEVER; STREPTOCOCCUS PYOGENES;

EID: 84877958866     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1906.121020     Document Type: Article

References (34)

1. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13:470-511. http://dx.doi.org/10.1128/CMR.13.3.470-511.2000
2. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685-94. http://dx.doi.org/10.1016/S1473-3099(05)70267-X
3. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective populationbased study. JAMA. 1993;269:384-9. http://dx.doi.org/10.1001/jama.1993.03500030082037
4. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1987;317:146-9. http://dx.doi.org/10.1056/NEJM198707163170305
5. Bisno AL, Brito MO, Collins CM. Molecular basis of group A streptococcal virulence. Lancet Infect Dis. 2003;3:191-200. http://dx.doi.org/10.1016/S1473-3099(03)00576-0
6. Whitnack E, Beachey EH. Inhibition of complement-mediated opsonization and phagocytosis of Streptococcus pyogenes by D fragments of fibrinogen and fibrin bound to cell surface M protein. J Exp Med. 1985;162:1983-97. http://dx.doi.org/10.1084/jem.162.6.1983
7. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A. 1988;85:1657-61. http://dx.doi.org/10.1073/pnas.85.5.1657
8. Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against nonvaccine serotypes of group A streptococci. Vaccine. 2011;29:8175-8. http://dx.doi.org/10.1016/j.vaccine.2011.09.005
9. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis. 2009;9:611-6. http://dx.doi.org/10.1016/S1473-3099(09)70178-1
10. Centers for Disease Control and Prevention. Introduction to emm typing: M protein gene (emm) typing Streptococcus pyogenes. 2008 [cited 2012 Apr 25]. http://www.cdc.gov/ncidod/biotech/strep/M-ProteinGene_typing.htm
11. Meisal R, Andreasson IK, Hoiby EA, Aaberge IS, Michaelsen TE, Caugant DA. Streptococcus pyogenes isolates causing severe infections in Norway in 2006 to 2007: emm types, multilocus sequence types, and superantigen profiles. J Clin Microbiol. 2010;48:842-51. http://dx.doi.org/10.1128/JCM.01312-09
12. O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis. 2007;45:853-62. http://dx.doi.org/10.1086/521264
13. Ma Y, Yang Y, Huang M, Wang Y, Chen Y, Deng L, et al. Characterization of emm types and superantigens of Streptococcus pyogenes isolates from children during two sampling periods. Epidemiol Infect. 2009;137:1414-9. http://dx.doi.org/10.1017/S0950268809002118
14. Tewodros W, Kronvall G. M protein gene (emm type) analysis of group A beta-hemolytic streptococci from Ethiopia reveals unique patterns. J Clin Microbiol. 2005;43:4369-76. http://dx.doi.org/10.1128/JCM.43.9.4369-4376.2005
15. Fraser JD, Proft T. The bacterial superantigen and superantigenlike proteins. Immunol Rev. 2008;225:226-43. http://dx.doi.org/10.1111/j.1600-065X.2008.00681.x
16. Sriskandan S, Faulkner L, Hopkins P. Streptococcus pyogenes: insight into the function of the streptococcal superantigens. Int J Biochem Cell Biol. 2007;39:12-9. http://dx.doi.org/10.1016/j.biocel.2006.08.009
17. Montes M, Ardanuy C, Tamayo E, Domenech A, Linares J, Perez-Trallero E. Epidemiological and molecular analysis of Streptococcus pyogenes isolates causing invasive disease in Spain (1998-2009): comparison with non-invasive isolates. Eur J Clin Microbiol Infect Dis. 2011;30:1295-302. http://dx.doi.org/10.1007/s10096-011-1226-x
18. Tanz RR, Shulman ST, Shortridge VD, Kabat W, Kabat K, Cederlund E, et al. Community-based surveillance in the United States of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons. Clin Infect Dis. 2004;39:1794-801. http://dx.doi.org/10.1086/426025
19. Liu X, Shen X, Chang H, Huang G, Fu Z, Zheng Y, et al. High macrolide resistance in Streptococcus pyogenes strains isolated from children with pharyngitis in China. Pediatr Pulmonol. 2009;44:436-41. http://dx.doi.org/10.1002/ppul.20976
20. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999;18:1096-100. http://dx.doi.org/10.1097/00006454-199912000-00014
21. Ministry of Health of China. Incidence of notifiable infectious diseases in China in May, 2011 [cited 2012 Apr 25]. http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohjbyfkzj/s3578/201106/52004.htm
22. Centers for Disease Control and Prevention. Streptococcus pyogenes emm sequence database. 2008 [cited 2012 Apr 25]. http://www.cdc.gov/ncidod/biotech/strep/protocol_emm-type.htm
23. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-first international supplement M100-S21. Wayne (PA): The Institute; 2011.
24. Theresa Lamagni JD, George R, Efstratiou A. Analysis of epidemiological patterns during a century of scarlet fever. 2008 [cited 2012 Apr 25]. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1229594253740
25. World Health Organization, Western Pacific Region. Scarlet fever: July 2011 [cited 2012 Apr 25]. http://www.wpro.who.int/mediacen-tre/factsheets/fs_20120301_ScarletFever/en/index.html
26. Liang Y, Shen X, Huang G, Wang C, Shen Y, Yang Y. Characteristics of Streptococcus pyogenes strains isolated from Chinese children with scarlet fever. Acta Paediatr. 2008;97:1681-5. http://dx.doi.org/10.1111/j.1651-2227.2008.00983.x
27. Liang Y, Liu X, Chang H, Ji L, Huang G, Zhou F, et al. Epidemiological and molecular characteristics of clinical isolates of Streptococcus pyogenes from Chinese children between 2005 and 2008. J Med Microbiol. 2012;61:975-83. http://dx.doi.org/10.1099/jmm.0.042309-0
28. Tse H, Bao JY, Davies MR, Maamary P, Tsoi HW, Tong AH, et al. Molecular characterization of the 2011 Hong Kong scarlet fever outbreak. J Infect Dis. 2012;206:341-51. http://dx.doi.org/10.1093/infdis/jis362
29. Luk EY, Lo JY, Li AZ, Lau MC, Cheung TK, Wong AY, et al. Scarlet fever epidemic, Hong Kong, 2011. Emerg Infect Dis. 2012;18:1658-61. http://dx.doi.org/10.3201/eid1810.111900
30. Chen M, Yao W, Wang X, Li Y, Chen M, Wang G, et al. Outbreak of scarlet fever associated with emm12 type group A Streptococcus in 2011 in Shanghai, China. Pediatr Infect Dis J. 2012;31:e158-62. http://dx.doi.org/10.1097/INF.0b013e31825874f3
31. Shea PR, Ewbank AL, Gonzalez-Lugo JH, Martagon-Rosado AJ, Martinez-Gutierrez JC, Rehman HA, et al. Group A Streptococcus emm gene types in pharyngeal isolates, Ontario, Canada, 2002-2010. Emerg Infect Dis. 2011;17:2010-7. http://dx.doi.org/10.3201/eid1711.110159
32. Luca-Harari B, Darenberg J, Neal S, Siljander T, Strakova L, Tanna A, et al. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol. 2009;47:1155-65. http://dx.doi.org/10.1128/JCM.02155-08
33. Commons R, Rogers S, Gooding T, Danchin M, Carapetis J, Robins-Browne R, et al. Superantigen genes in group A streptococcal isolates and their relationship with emm types. J Med Microbiol. 2008;57:1238-46. http://dx.doi.org/10.1099/jmm.0.2008/001156-0
34. Rivera A, Rebollo M, Miro E, Mateo M, Navarro F, Gurgui M, et al. Superantigen gene profile, emm type and antibiotic resistance genes among group A streptococcal isolates from Barcelona, Spain. J Med Microbiol. 2006;55:1115-23. http://dx.doi.org/10.1099/jmm.0.46481-0